Which peptides did the FDA committee vote on in July 2026?
Disclosure: Dr. Peppa is owned and operated by Medtruva LLC, which sells peptide products, including some compounds discussed on this site. Advertisements are labeled.
The short answer
- Seven peptides were reviewed on July 23–24, 2026 by FDA's Pharmacy Compounding Advisory Committee.
- Six received favorable votes. Emideltide was the only one rejected.
- FDA's own scientific reviewers had recommended against all seven.
- The votes are non-binding. As of late September 2026, no rule has followed, so nothing has changed legally.
What the committee was deciding
Not whether to approve these peptides as drugs. The question was whether each should go on the 503A bulks list, which names ingredients compounding pharmacies may use to make medications for individual patients even though the ingredient isn't part of an approved drug.
FDA's scientific staff reviewed each compound first and proposed that none be added.
The votes
| Peptide | Nominated for | Vote | Outcome |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8–6–1 | Recommended |
| KPV | Wound healing and inflammatory conditions | 8–6–1 | Recommended |
| TB-500 | Wound healing | 8–6–1 | Recommended |
| MOTS-c | Obesity and osteoporosis | 7–5–2 | Recommended |
| Emideltide (DSIP) | Sleep | 6–7–1 | Not recommended |
| Epitalon | — | 7–4–1 | Recommended |
| Semax | — | 8–5–1 | Recommended |
Vote counts are as reported by news outlets and legal analysts covering the meeting. FDA has not published official minutes.
What FDA's reviewers found
The briefing documents are public, and they are blunt about the evidence:
- BPC-157: molecular targets "have not been identified"; the main human report is a conference abstract in 53 people with ulcerative colitis, given as an enema.
- KPV: FDA "did not find information on products containing KPV… administered in humans."
- TB-500: no clinical studies or human exposure data by any route, and FDA notes TB-500 and thymosin beta-4 "are not the same substance."
- MOTS-c: same finding, no human exposure data.
- Emideltide: sleep effects are consistent in animals, but human evidence is "insufficient," with studies that were "inconclusive and at best preliminary."
Who voted
The committee that met in July had 11 regular voting members, eight of whom had been seated within the previous few months, along with eight temporary members added for this meeting, most limited to specific compounds.
NBC News reported that on BPC-157, KPV and TB-500, all eight of the new appointees voted yes. Since each of those votes had exactly eight yes votes, the new members accounted for all of them.
Several of those members run clinics or pharmacies in fields that could benefit from wider peptide access, which drew criticism before the meeting. Reporting also noted that FDA officials had raised conflict-of-interest concerns about the panel's composition.
What has happened since
Nothing legally binding. Advisory committees make recommendations. Adding a substance to the 503A list requires formal rulemaking with a public comment period.
As of late September 2026, no proposed or final rule has been published. The compounds remain off the list pharmacies may use.
Separately, FDA has continued enforcement against sellers. On August 24, 2026 it issued warning letters to several peptide vendors, treating products including BPC-157 and SS-31 as unapproved new drugs.
Sources
- FDA, July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- FDA, Briefing document: introduction and FDA proposals — https://www.fda.gov/media/193342/download
- FDA, Briefing document: BPC-157 — https://www.fda.gov/media/193343/download
- FDA, Briefing document: KPV — https://www.fda.gov/media/193346/download
- FDA, Briefing document: MOTS-c — https://www.fda.gov/media/193347/download
- FDA, Briefing document: TB-500 — https://www.fda.gov/media/193349/download
- FDA, Briefing document: emideltide — https://www.fda.gov/media/193344/download
- FDA, Certain bulk drug substances that may present significant safety risks — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- NBC News, FDA panel recommends peptides over scientists' objections (23 July 2026) — https://www.nbcnews.com/health/health-news/peptides-restrictions-ease-fda-panel-recommend-bpc-157-scientists-rcna588879
- McDermott Will & Schulte, PCAC backs majority of peptides (27 July 2026) — https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/
- FDA, Warning Letter to Royal Peptides LLC (24 August 2026) — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026